Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse

被引：122

作者：

Bernard, Sophie ^{[1
,2
]}

Goldwirt, Lauriane ^{[3
]}

Amorim, Sandy ^{[1
,2
]}

Brice, Pauline ^{[1
]}

Briere, Josette ^{[4
]}

de Kerviler, Eric ^{[5
]}

Mourah, Samia ^{[2
,6
,7
]}

Sauvageon, Helene ^{[3
]}

Thieblemont, Catherine ^{[1
,2
]}

机构：

[1] Hosp Saint Louis, APHP, Hemato Oncol Dept, Paris, France

[2] Paris Diderot Univ, Sorbonne Paris Cite, Paris, France

[3] Hosp St Louis, APHP, Dept Pharmacol, Paris, France

[4] Hosp St Louis, APHP, Dept Pathol, Paris, France

[5] Hosp St Louis, APHP, Dept Radiol, Paris, France

[6] Hosp St Louis, UMR S 976, INSERM, Paris, France

[7] Hosp St Louis, APHP, Pharmacol Genet Lab, Paris, France

来源：

BLOOD | 2015年 / 126卷 / 14期

关键词：

NON-HODGKIN-LYMPHOMA; TYROSINE KINASE; TARGETING BTK; MALIGNANCIES; PCI-32765;

D O I：

10.1182/blood-2015-05-647834

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The risk of central nervous system (CNS) dissemination in mantle cell lymphoma (MCL) is low and occurs late in the course of the disease. However, prognosis in such cases remains extremely poor despite high-dose antimetabolite chemotherapy. Among novel drugs used to treat relapsing MCL patients, ibrutinib, an oral inhibitor of Bruton tyrosine kinase, shows great promise. Here we report the clinical observation of 3 MCL patients with symptomatic CNS relapse treated with single-agent ibrutinib. All 3 patients had dramatic and rapid responses with almost immediate recovery from symptoms. We also confirmed that ibrutinib crosses the blood-brain barrier with parallel pharmacokinetic analyses in plasma and cerebrospinal fluid using a validated LC-MS/MS method. All responses were ongoing after 2 months to 1 year of follow-up.

引用

页码：1695 / 1698

页数：4

共 17 条

[1] Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [J].

Advani, Ranjana H. ;

Buggy, Joseph J. ;

Sharman, Jeff P. ;

Smith, Sonali M. ;

Boyd, Thomas E. ;

Grant, Barbara ;

Kolibaba, Kathryn S. ;

Furman, Richard R. ;

Rodriguez, Sara ;

Chang, Betty Y. ;

Sukbuntherng, Juthamas ;

Izumi, Raquel ;

Hamdy, Ahmed ;

Hedrick, Eric ;

Fowler, Nathan H. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :88-94

[2]

[Anonymous], 2001, GUID IND BIOAN METH

[3] Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: An analysis of 3,258 patients in a single center [J].

Aviles, Agustin ;

Jesus Nambo, M. ;

Neri, Natividad .

MEDICAL ONCOLOGY, 2013, 30 (02)

[4] Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia [J].

Byrd, John C. ;

Furman, Richard R. ;

Coutre, Steven E. ;

Flinn, Ian W. ;

Burger, Jan A. ;

Blum, Kristie A. ;

Grant, Barbara ;

Sharman, Jeff P. ;

Coleman, Morton ;

Wierda, William G. ;

Jones, Jeffrey A. ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Johnson, Amy J. ;

Sukbuntherng, Juthamas ;

Chang, Betty Y. ;

Clow, Fong ;

Hedrick, Eric ;

Buggy, Joseph J. ;

James, Danelle F. ;

O'Brien, Susan .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (01) :32-42

[5] Mantle cell lymphoma: evolving management strategies [J].

Campo, Elias ;

Rule, Simon .

BLOOD, 2015, 125 (01) :48-55

[6] Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network [J].

Cheah, C. Y. ;

George, A. ;

Gine, E. ;

Chiappella, A. ;

Kluin-Nelemans, H. C. ;

Jurczak, W. ;

Krawczyk, K. ;

Mocikova, H. ;

Klener, P. ;

Salek, D. ;

Walewski, J. ;

Szymczyk, M. ;

Smolej, L. ;

Auer, R. L. ;

Ritchie, D. S. ;

Arcaini, L. ;

Williams, M. E. ;

Dreyling, M. ;

Seymour, J. F. .

ANNALS OF ONCOLOGY, 2013, 24 (08) :2119-2123

[7] Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].

Cheson, Bruce D. ;

Fisher, Richard I. ;

Barrington, Sally F. ;

Cavalli, Franco ;

Schwartz, Lawrence H. ;

Zucca, Emanuele ;

Lister, T. Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+

[8]

FDA, 2013, CLIN PHARM REV IBR

[9]

Goldwirt L, 2015, 1 INT WORKSH TARG DR

[10] Targeting Bruton's tyrosine kinase in B cell malignancies [J].

Hendriks, Rudi W. ;

Yuvaraj, Saravanan ;

Kil, Laurens P. .

NATURE REVIEWS CANCER, 2014, 14 (04) :219-232

← 1 2 →